

# Occupational Health Update: Acute Care Facilities 4/28/26

Erica Pettigrew, MD, JD, MPH


Associate Professor, UNC Dept of Family Medicine

Medical Director, Orange County Health Department


Medical Director, Occupational Health at UNC Medical Center



SCHOOL OF  
MEDICINE



## Disclosures



- No financial relationships to disclose
- No off-label or investigational use of medications and/or devices
- The information and views set out in this presentation are those of the author and do not necessarily reflect the official opinion of the University of North Carolina at Chapel Hill or UNC Health



## Objectives



- Vaccine Overview in US
- Vaccines for HCPs (Pre-exposure prophylaxis)
- Post-exposure prophylaxis (Bloodborne Pathogens)
- Tuberculosis
- Employee Well-Being




# How Do We Know Vaccines Really Work?



DISEASE	PRE-VACCINE ERA ESTIMATED ANNUAL MORBIDITY <sup>1</sup>	MOST RECENT REPORTS OR ESTIMATES OF U.S. CASES	PERCENT DECREASE
Diphtheria	21,053	2 <sup>2</sup>	>99%
<i>H. influenzae</i> serotype B (invasive, <5 years of age)	20,000	18 <sup>2</sup>	>99%
Hepatitis A	117,333	(est) 37,700 <sup>3</sup>	68%
Hepatitis B (acute)	66,232	(est) 20,700 <sup>3</sup>	69%
Measles	530,217	1,275 <sup>2</sup>	>99%
Meningococcal disease (all serotypes)	2,886 <sup>4</sup>	371 <sup>2</sup>	87%
Mumps	162,344	3,780 <sup>2</sup>	98%
Pertussis	200,752	18,617 <sup>2</sup>	91%
Pneumococcal disease (invasive, <5 years of age)	16,069	1,700 <sup>5</sup>	89%
Polio (paralytic)	16,316	0 <sup>2</sup>	100%
Rotavirus (hospitalizations, <3 years of age)	62,500 <sup>6</sup>	30,625 <sup>7</sup>	51%
Rubella	47,745	6 <sup>2</sup>	>99%
Congenital Rubella Syndrome	152	1 <sup>2</sup>	>99%
Smallpox	29,005	0 <sup>2</sup>	100%
Tetanus	580	26 <sup>2</sup>	96%
Varicella	4,085,120	8,297 <sup>8</sup>	>99%

<https://www.immunize.org/wp-content/uploads/catg.d/p4037.pdf>





# Vaccines Indicated for Healthcare Personnel



## HCP Routine and Special Vaccines



- Healthcare personnel should be up to date on all the routine immunizations recommended for their age and medical conditions
- Some vaccines, such as flu and covid, are recommended for everyone but are often specifically promoted or mandated for HCPs because of decrease in nosocomial spread
- A few vaccines may be particularly indicated for those who work in healthcare



 PROJECT  
**FIRST LINE**

*Healthcare Workers*

**Get your updated  
vaccines this  
respiratory  
virus season**



## Onboarding HCPs Through Occupational Health



- Only pertinent federal regulation is that OSHA requires Hep B education and vaccine availability
- Flu vaccine uptake among HCPs to NHSN is a mandatory report for CMS-certified facilities
- Most hospitals have internal processes that govern which vaccines are conditions of employment

<https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030> accessed 4/7/26

<https://www.cdc.gov/nhsn/pdfs/hps-manual/vaccination/hps-flu-vaccine-protocol-508.pdf> accessed 4/7/26

# HCP Vaccination Recommendations



Vaccination	Recommendation
COVID-19	Everyone 6 months+ should get at least one dose of newest formulation
Hepatitis B	If no prior dose, either 2 doses of Heplisav-B or 3-dose series of either Engerix or Recombivax Obtain serology 1-2 months after final dose
Influenza	Give 1 dose annually
MMR	HCP born in 1957 or later need 2-doses of MMR, 4 weeks apart if no prior immunity or vaccination. Before 1957, consider serology testing and dosing if needed
Varicella	If no prior infection, serologic immunity, prior vaccination, give 2 doses of varicella vaccine 4 weeks apart
Tetanus, diphtheria, pertussis	Give 1 dose to all who have not received previously. Each pregnancy. Booster every 10 years (Tdap preferred over Td)
Meningococcal	Microbiologists exposed to isolates of <i>N. Meningitidis</i>
Mpox	Microbiologists/lab workers exposed to Mpox
Polio	HCPs: 3 dose primary series & can have one lifetime booster if at increased risk

## ACIP Feb 2023 Update



- **JYNNEOS for Monkeypox**
  - Two vaccines (JYNNEOS and ACAM2000) for orthopoxviruses (including MPX and smallpox). JYNNEOS w/ much less contraindications.
  - Pre- or post- exposure prophylaxis indications based on risk factors (generally intimate, prolonged contact)
  - Most healthcare workers do not need to get this vaccine. Exceptions include HCPs w high risk exposure (caring for +pt for prolonged period without PPE) and lab personnel handling specimens

<https://www.cdc.gov/mmwr/volumes/71/wr/mm7122e1.htm>

## COVID Vaccines



- So wait – I thought it wasn't required anymore for healthcare personnel?
  - The federal CMS regulation which had required all HCPs to be covid vaccinated has been retired. Individual hospitals, LTC companies, etc can decide to have it be an internal condition of employment if they wish.

# Hepatitis B



- **Indications**
  - Universal; HCP with potential blood exposure (OSHA required OR signed refusal)
- **Administration**
  - Prior to administration do not routinely perform serologic screening for HB unless cost effective
  - After last dose in the series, test for immunity ( $>10$  mIU/mL); if inadequate provide one more series and test again for immunity; if inadequate test consider as “non-responder”
  - If non-immune after two series, test for HBsAg

# Hepatitis B



- HEPLISAV-B approved in late 2017, updated 2024 to include pregnant people
- Adults > 18 years of age
- Two doses one month apart

**Table 7**  
**Study 3: Seroprotection Rates of HEPLISAV-B and Engerix-B<sup>a</sup>**  
**(ages 18 - 70 years)**

Age (years)	HEPLISAV-B <sup>a</sup>		Engerix-B <sup>a</sup>		Difference in SPRs (HEPLISAV-B minus Engerix-B)
	N	SPR (95% CI)	N	SPR (95% CI)	Difference (95% CI)
	18-29	174	100.0% (97.9, 100.0)	99	93.9% (87.3, 97.7)
30-39	632	98.9% (97.7, 99.6)	326	92.0% (88.5, 94.7)	6.9% (4.2, 10.4)*
40-49	974	97.2% (96.0, 98.2)	518	84.2% (80.7, 87.2)	13.1% (9.9, 16.6)*
50-59	1439	95.2% (94.0, 96.3)	758	79.7% (76.6, 82.5)	15.5% (12.6, 18.7)*
60-70	1157	91.6% (89.9, 93.1)	588	72.6% (68.8, 76.2)	19.0% (15.2, 23.0)*


<https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM584762.pdf>

[https://www.cdc.gov/mmwr/volumes/73/wr/mm7348a3.htm#:~:text=These%20available%20ata%2C%20primarily%20for%20persons%20who,vaccinate%20pregnant%20persons%20needing%20HepB%20vaccination%20\(3%20C4\).](https://www.cdc.gov/mmwr/volumes/73/wr/mm7348a3.htm#:~:text=These%20available%20ata%2C%20primarily%20for%20persons%20who,vaccinate%20pregnant%20persons%20needing%20HepB%20vaccination%20(3%20C4).) Accessed 4/7/26

# Influenza Season 25-26




Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, 2025-2026 Season



- Eleven influenza-associated pediatric deaths occurring during the 2025-2026 season were reported to CDC this week, bringing the season total to 90 reported influenza-associated pediatric deaths.
- Among children who were eligible for influenza vaccination and with known vaccination status, approximately 85% of reported pediatric deaths this season have occurred in children who were not fully vaccinated against influenza.

<https://www.cdc.gov/fluview/surveillance/2026-week-08.html> accessed 4/7/26

# ACIP August 2022 Update




**UPDATED 2022-2023**

## INFLUENZA VACCINE RECOMMENDATIONS

**Look for specific updates, including:**

- 3 vaccines preferentially recommended for people 65 and older
- Vaccine composition updated to better protect against flu viruses expected to circulate this season

**CDC recommends everyone 6 months and older get an annual flu vaccine**



bit.ly/rr7101a1  
AUGUST 26, 2022

**MMWR**



Every year individuals around the world work to study, track, and prevent flu. This page profiles these Flu Fighters and the work they are doing to contribute to flu prevention in the U.S. and around the world!

A **FLU**  
VACCINE  
CAN TAKE  
FLU FROM

**WILD**  
TO  
*mild*








#FIGHT FLU

UNC  
SCHOOL OF  
MEDICINE

CDC

UNC  
SCHOOL OF  
MEDICINE

Centers for Disease Control and Prevention  
**MMWR** | **ALL HEALTHCARE WORKERS NEED FLU VACCINES**

VACCINATING HEALTHCARE WORKERS	3 OF 4 HEALTHCARE WORKERS GET FLU VACCINES	WORKPLACE STRATEGIES CAN HELP!
 <b>REDUCES</b> FLU AMONG WORKERS	<b>HIGHEST WHEN</b> EMPLOYER REQUIRED VACCINE OR GAVE ONSITE	 <b>PROMOTE</b> ON-SITE VACCINATION
 <b>REDUCES</b> WORK ABSENCES		 <b>OFFER</b> LOW OR NO COST VACCINES
 <b>PROTECTS</b> PATIENTS	<b>LOWEST FOR</b> LONG-TERM CARE WORKERS	 <b>REMEMBER</b> NON-CLINICAL STAFF

## Influenza vaccines



- One annual dose for all persons  $\geq$  6 months of age (sometimes 2 doses for kids)
- Required for residents and HCP in ECFs in NC (1 N.C. Gen. Stat. Ann. § 131E-113(a))
- Required in SC LTC (S.C. Code Ann. Regs. 61-17)
- No legal mandates for other healthcare workers
- Immunize as soon as vaccine becomes available for the current season

<https://www.cdc.gov/acip-recs/hcp/vaccine-specific/flu.html>

# Measles, Mumps, Rubella (MMR)

- **Measles**
  - Born before 1957: Consider immune (except during outbreak): Born after 1957: 2 doses
  - Immunity = Appropriate immunizations or positive serology
- **Mumps**
  - Born before 1957: Consider immune (except during outbreak): Born after 1957: 2 doses.
  - 3<sup>rd</sup> dose considered in outbreak settings.
  - Immunity = Appropriate immunizations or positive serology
- **Rubella**
  - 1 dose of MMR to susceptible women of childbearing potential
  - Immunity = Appropriate immunizations or positive serology




# Measles is coming back



## Yearly measles cases

as of April 2, 2026



Very contagious: 9 out of 10 susceptible people who are exposed will contract measles

<https://www.cdc.gov/measles/data-research/index.html> accessed 4/7/26

# Measles




## U.S. Cases

	2026 To date	2025 Full year
<b>Total Cases</b>	<b>1,671</b>	<b>2,286</b>
<b>Age</b>		
Under 5 years	346 (21%)	584 (26%)
5-19 years	868 (52%)	1,015 (44%)
20+ years	452 (27%)	674 (29%)
Age unknown	5 (0%)	13 (1%)
<b>Vaccination Status</b>		
Unvaccinated or Unknown	92%	93%
One MMR dose	4%	3%
Two MMR doses	4%	4%


If you suspect a case of measles in your facility, call your local health department or NC Epi On Call 919-733-3419 IMMEDIATELY 24/7 (not days or hours later)

<https://www.cdc.gov/measles/data-research/index.html> accessed 4/7/26


Kindergartners with Up to Date status by County in 2024



All Kindergarten Compliance, 2024



State Kindergarten Compliance, 2024




# Herd Immunity Goal?


<https://immunization.dph.ncdhhs.gov/schools/kindergartendashboard.htm>  
accessed 4/7/26

# NC Kindergarten Vaccine Exemption

Exemptions by Type and Year



Exempt by School Type and Year



<https://www.dph.ncdhs.gov/programs/epidemiology/immunization/data/kindergarten-dashboard> accessed 4/7/26



## Measles Prep Plan – Sense of Urgency

- Educational campaigns aimed at HCPs on early recognition - every minute that goes by with an undiagnosed measles patient in your facility is exposing more and more people
- Fast-paced contact investigations. Coordination between OHS, IP, Plant Engineering and health dept along with immediate availability of immunoglobulin and MMR (window for post-exposure ppx in most cases is 72 hours)
- Practice drills at all entry points (outpatient, ED, urgent care) after protocols are developed (isolate suspected pt in neg pressure room, call IP/Epi-On-Call, etc)
- Occupational Health:
  - Maintain up-to-date records of all employes
  - Review records now and offer MMR doses to those out of compliance
  - If your facility might care for a measles patient:
    - Maintain list of those with approved exemptions (key since CDC recommends only immune HCPs provide measles care)
    - Discuss how to address immunocompromised HCPs who want to opt out

# Varicella




- **Special consideration should be given to those who have close contact with**
  - Persons at high risk for severe disease (e.g., immunocompromised persons)
  - Persons are at high risk for exposure or transmission (e.g., teachers of young children, college students, military recruits, international travelers)
- **Immunity**
  - 2 doses of vaccine (gold standard), positive serology. Could also accept history of varicella if lab confirmed or epi-linked, but verbal report “I had chicken pox as a kid” doesn’t count.
  - Receiving Shingrix vaccine does not count as immunity for varicella



<https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6007a1.htm>

# Varicella



## Tetanus-diphtheria-acellular pertussis (Tdap)



- **Substitute 1 dose Tdap for all adults when Td booster due if no history of Tdap.**
  - May be used to provide tetanus PEP
  - Provide to all adults with exposure to young children (no delay after Td)
  - Also recommended for pregnant people in each pregnancy (preferably 27-36 weeks gestational age)
  - Employees who are 10 years out from Tdap can be boosted with Td or Tdap (but Tdap preferred)

# Meningococcal Vaccine



- Recommended for adults had high risk of disease (persistent complement deficiency, functional or anatomic asplenia, or HIV infection (adolescents)).
  - Two vaccines series are needed: MenACWY and Serogroup B (MenB)
- MenACWY
  - Immunosuppressed – 2 doses of MenACWY and boosters every 5 years, 2 or 3-dose MenB
  - **Microbiologists – 1 dose, booster every 5 years (MenACWY), 2 or 3-dose MenB**
    - **Now they could get the combo MenABCWY vaccine when both are indicated**
  - Anatomic/functional asplenia patients should be vaccinated against MenACWY/MenB



# Tuberculosis



TAKE  
ON **TB**

To eliminate tuberculosis (TB),  
we must prioritize groups at  
increased risk of TB

Living in congregate settings is a risk factor for TB disease:



Homeless Shelters



Correctional Facilities



Long-term Care  
Facilities

[www.cdc.gov/tb](http://www.cdc.gov/tb)



Centers for Disease  
Control and Prevention  
National Center for HIV, Viral  
Hepatitis, STD, and TB Prevention

## Testing/ Treatment



- **Baseline (preplacement) screening and testing.** All U.S. health care personnel should have baseline TB screening, including an individual risk assessment, which is necessary for interpreting any test result. IGRAs (quant gold or T spot) or tb skin tests can be used. Follow CDC algorithm for interpretation.
- **Serial screening and testing for health care personnel without LTBI is NOT indicated.** In the absence of known exposure or evidence of ongoing TB transmission, U.S. health care personnel (as identified in the 2005 guidelines) without LTBI should not undergo routine serial TB screening or testing at any interval after baseline (e.g., annually.) Could consider annual screening with high risk groups like respiratory therapists.
- **Health care personnel with LTBI and no prior treatment** should be offered, and strongly encouraged to complete treatment with a recommended regimen, including short-course treatments, unless a contraindication exists

Sosa LE, Njie GJ, Lobato MN, et al. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep 2019;68:439-443. DOI: <http://dx.doi.org/10.15585/mmwr.mm6819a3external icon>.

## NC TB Policy Manual



- **Patients in long term care facilities**
  - Testing upon admission (two-step TST or IGRA). Annual screening which can be accomplished by a verbal elicitation of symptoms.
    - 10A NCAC 41A .0205; 10A NCAC 13D .2202 & .2209
- **Long term care facility employees**
  - Testing upon employment (two-step for TST or IGRA) and after any exposures. Annual education.
    - 10A NCAC 41A .0205; 10A NCAC 13D .2202 & .2209; OSHA

<https://epi.dph.ncdhhs.gov/cd/lhds/manuals/tb/COVIDvaxMemo01282021.pdf>

## Fit Testing



- If employees may need to wear respirators as part of their PPE (i.e. for caring for COVID patients), then they need to be annually fit tested through your respiratory protection program.
- Medical clearance for N95s is not complicated – there really aren't medical conditions which affirmatively preclude the use of an N95 except anatomical challenges.



# Bloodborne Pathogens



## Bloodborne Pathogens




- Approximately 385,000 needle sticks and other sharps-related injuries to hospital-based healthcare personnel each year.
- 58 total known occupationally acquired HIV cases in HCPs; all but 1 were prior to 1999.
- 88% (50/57) of the documented cases of occupational HIV transmission from 1985-2004 involved a percutaneous exposure. Of those, 45/57 involved a hollow-borne needle.
- 41% of sharp injuries occur during use; 40% after use/before disposal; 15% during/after disposal

<https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6353a4.htm>

## Steps for Prevention

- Needleless devices
- Single-hand recapping
- Handwashing stations
- Sharps containers
- Laundry
- Disposal of contaminated material
- Mask, eye protection, gloves, & face shields



## OSHA Bloodborne Pathogens Standard



- Employers must establish a written exposure control plan and provide annual training
- Mandates use of universal precautions (all body fluids assumed contaminated except sweat)
- Employers must utilize engineering and work practice controls to minimize/eliminate exposure

**(e-CFR 1910.1013)**

<https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1030>

## OSHA Bloodborne Pathogens Standard



- Requires offering hepatitis B vaccine to persons with the potential for exposure
- Testing of exposed employees for Hepatitis B and HIV
- Post-exposure prophylaxis must be immediately available as per CDC guidelines
- All work-related needle stick injuries and cuts from sharp objects that are contaminated with another person's blood or other potentially infectious material are OSHA-reportable regardless of the source patient disease status.

(e-CFR 1910.1013)

# Bloodborne Pathogens



- **Risk (percutaneous exposure)**

HBV

- 22.0 – 30.0% (HBeAG<sup>+</sup>)
- 1.0 – 6.0% (HBeAG<sup>-</sup>)

HCV

- 1.8%

HIV

- 0.3% (1 in 300)

- **Risk (mucous membrane)**

HBV

- Yes (rate unknown)

HCV

- Yes (rate unknown but very small)

HIV

- 0.1% (1 in 1000)
- < 0.1% (non-intact skin)

R  
I  
S  
K

- Test source for hepatitis B (HBsAg), hepatitis C (HCV PCR), HIV (4<sup>th</sup> gen, HIV antibodies and p24 antigen)
- Provide hepatitis B prophylaxis, if indicated
- Provide follow-up for hepatitis C, if indicated
- If source HIV+ or at "high risk" for HIV, offer employee HIV prophylaxis per CDC protocol

CDC, 2003

## Updated HIV oPEP Guidelines (Finally!)



Key updates include:

- **New antiretroviral regimens for PEP** based on low rates of side effects and convenient dosing schedules.
- **Shortened duration of follow-up HIV testing** after occupational exposure.
- **Elimination of routine follow-up laboratory testing** for antiretroviral drug toxicity when baseline testing is normal and no signs or symptoms of toxicity develop during PEP.
- **Considerations for PEP in cases where the source patient has an undetectable viral load.**
- **Guidance for healthcare personnel already on pre-exposure prophylaxis (PrEP)** at the time of occupational exposure.

<https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/2025-us-public-health-service-guidelines-for-the-management-of-occupational-exposures-to-human-immunodeficiency-virus-and-recommendations-for-postexposure-prophylaxis-in-healthcare-settings/A410E90C8C13C8B9FB417C7F42051D2A> accessed 4/7/26

# Post-exposure Pathway



Infection Status of Source Patient ↓	Baseline Labs	2 Weeks	4 Weeks	6 Weeks	4 Months	6 Months
DATE: →	__/__/__	__/__/__	__/__/__	__/__/__	__/__/__	__/__/__
<b>HIV positive</b>	HIV test – 4 <sup>th</sup> generation	Lab - only if baseline abnormal or clinical indication		HIV test - 4 <sup>th</sup> generation	HIV test - 4 <sup>th</sup> generation	
<b>HBsAg positive</b>	<ul style="list-style-type: none"> <li>If source positive and HCP unknown, need HBsAb.</li> <li>If HBsAb ≥12 mIU/mL - testing complete.</li> <li>If HBsAb &lt;12 mIU/mL, need anti-HBc &amp; HBsAg at baseline</li> </ul>	Lab - only if baseline abnormal or clinical indication				<ul style="list-style-type: none"> <li>Anti-HBc</li> <li>HBsAg</li> </ul>
<b>Hepatitis C RNA PCR positive</b>	Anti-HCV (Hepatitis C antibody)	Lab - only if baseline abnormal or clinical indication		HCV RNA PCR	Anti-HCV (Hepatitis C antibody)	
<b>Unknown source</b>	<ul style="list-style-type: none"> <li>HIV test – 4<sup>th</sup> generation</li> <li>If source unknown and HCP HBsAb unknown, need HBsAb.</li> <li>If HBsAb ≥12 mIU/mL - testing complete.</li> <li>If HBsAb &lt;12 mIU/mL, need anti-HBc &amp; HbsAg at baseline</li> <li>HCV antibody</li> </ul>	Lab - only if baseline abnormal or clinical indication		<ul style="list-style-type: none"> <li>HIV test – 4<sup>th</sup> generation</li> <li>HCV RNA PCR</li> </ul>	<ul style="list-style-type: none"> <li>HIV test – 4<sup>th</sup> generation</li> <li>Anti-HCV (Hepatitis C antibody)</li> </ul>	<ul style="list-style-type: none"> <li>Anti-HBc</li> <li>HBsAg</li> </ul>

## Current HIV PEP

- Three-drug regimen
  - Option 1: Biktarvy once daily x 28 days
  - Option 2: Truvada once daily + Tivicay once daily x 28 days
  - Old regimen: Tenofovir-emtricitabine (Truvada) + raltegravir (Isentress) for 4 weeks (28 days)
  - Other regimens are available for known HIV-source patients with specific drug resistance but these cases are rare.
  - Start within 72 hours

Group	Preferred <sup>1</sup> / Alternative <sup>2</sup>	Regimen
Healthcare personnel without conditions specified below	Preferred	Integrase Strand Transfer Inhibitors PLUS Two Nucleoside Reverse Transcriptase Inhibitors <ul style="list-style-type: none"> <li>• Bictegravir/emtricitabine/tenofovir alafenamide</li> <li>• Dolutegravir PLUS (tenofovir alafenamide OR tenofovir disoproxil fumarate) PLUS (emtricitabine OR lamivudine)</li> </ul>
	Alternative	Boosted Protease Inhibitor PLUS Two Nucleoside Reverse Transcriptase Inhibitors <ul style="list-style-type: none"> <li>• Darunavir and cobicistat OR darunavir and ritonavir PLUS (tenofovir alafenamide OR tenofovir disoproxil fumarate) PLUS (emtricitabine OR lamivudine)</li> </ul>



<https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/2025-us-public-health-service-guidelines-for-the-management-of-occupational-exposures-to-human-immunodeficiency-virus-and-recommendations-for-postexposure-prophylaxis-in-healthcare-settings/A410E90C8C13C8B9FB417C7F42051D2A> accessed 4/7/26

## Current HIV PEP



- 10A NCAC 41A .0202
- CONTROL MEASURES – HIV
  - When the source case is known, the attending physician or occupational health provider responsible for the exposed person shall notify the healthcare provider of the source case that an exposure has occurred.
  - This healthcare provider shall arrange HIV testing of the source person (unless known to be HIV+) and notify the OHS provider of the test results.
  - Source patient consent is **not required**

<http://reports.oah.state.nc.us/ncac/title%2010a%20-%20health%20and%20human%20services/chapter%2041%20-%20epidemiology%20health/subchapter%20a/10a%20ncac%2041a%20.0202.html>

## Hepatitis B



- Universal; HCP with potential blood exposure (OSHA required or HCP may decline)
  - No need to routinely obtain Hep B titers if an employee has documented vaccine series and a positive titer
  - In practice, we usually titer and give a booster if titer is  $< 10$  mIU/mL
  - For known non-responders, with exposure they should get Hepatitis B Immune Globulin (HBIG) within 24 hours (up to 7 days after exposure)

# Hepatitis B

	HBsAg	Anti-HBc	HBsAb*
Acute infection	Positive	IgM positive	Negative
Infection resolved	Negative	IgG Positive	Positive
Chronic infection	Positive	IgG Positive	Negative
Vaccinated	Negative	Negative	Positive
Susceptible	Negative	Negative	Negative

Otero, William, Parga, Julián, & Gastelbondo, Johanna. (2018). Serology of hepatitis B virus: multiple scenarios and multiple exams. *Revista colombiana de Gastroenterología*, 33(4), 411-422. <https://doi.org/10.22516/25007440.327>

<https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-10-hepatitis-b.html>

## Postexposure Management of Health Care Personnel after Occupational Exposure to Blood and Body Fluids, by Health Care Personnel HepB Vaccination and Response Status

HepB Vaccination and Response Status	Postexposure testing results for source patient (HBsAg)	Postexposure testing results for HCP (anti-HBs)	HBIG* postexposure prophylaxis	Vaccination postexposure prophylaxis	Postvaccination Serologic Testing <sup>1</sup>
Documented responder <sup>2</sup> after complete series (3 or more doses)	No action needed	No action needed	No action needed	No action needed	No action needed
Documented nonresponder <sup>3</sup> after 2 complete series	Positive/ unknown	**	2 doses HBIG separated by 1 month	No action needed	No action needed
	Negative	No action needed	No action needed	No action needed	No action needed
Response unknown after a complete series	Positive/ unknown	less than 10 mIU/mL**	1 dose HBIG	Initiate revaccination	Yes
	Negative	less than 10 mIU/mL	None	Initiate revaccination	Yes
	Any result	greater than or equal to 10 mIU/mL	No action needed	No action needed	No action needed
Unvaccinated/ incompletely vaccinated or vaccine refusers	Positive/ unknown	**	1 dose HBIG	Complete vaccination	Yes
	Negative	No action needed	None	Complete vaccination	Yes

\*HBIG should be administered intramuscularly as soon as possible after exposure when indicated. The effectiveness of HBIG when administered greater than 7 days after percutaneous, mucosal, or nonintact skin exposures is unknown. HBIG and HepB vaccine should be administered in separate anatomic injection sites.

<sup>1</sup>Should be performed 1 to 2 months after the last dose of the HepB vaccine series (and 4 to 6 months after administration of HBIG to avoid detection of passively administered anti-HBs) using a quantitative method that allows detection of the protective concentration of anti-HBs (greater than or equal to 10 mIU/mL).


<sup>2</sup>A responder is defined as a person with anti-HBs greater than or equal to 10 mIU/mL after 3 or more doses of HepB vaccine.

<sup>3</sup>A nonresponder is defined as a person with anti-HBs less than 10 mIU/mL after 2 complete series of HepB vaccine.

\*\*HCP who have anti-HBs less than 10 mIU/mL, or who are unvaccinated or incompletely vaccinated, and sustain an exposure to a source patient who is HBsAg-positive or has unknown HBsAg status, should undergo baseline testing for HBV infection as soon as possible after exposure and follow-up testing approximately 6 months later. Initial baseline tests consist of total anti-HBc; testing at approximately 6 months consists of HBsAg and total anti-HBc.

# Hepatitis C

- No post-exposure prophylaxis
- Source patients should be tested by Hep C PCR



## Follow-up Testing



- Hepatitis B
  - Not required if employee has immunity
- HIV
  - Dependent on source patient and available testing
- Hepatitis C
  - Dependent on source patient, test for HCV antibodies and HCV RNA

## Employee Well-being



- Could be its own lecture
- Taking good care of employees benefits all: patients, employees, and the business (safer environment, lower turnover, less staffing shortages)
- Physical and mental well-being
  - Living wages and robust benefits
  - Parental leave
  - Comprehensive DEI (diversity, equity and inclusion) trainings and meaningful reflections in workplace policies/practices, not just lip service
  - Safety from workplace violence
  - Fair PTO policies that disincentivize presenteeism
  - Access to resources for burnout, moral injury

# Presenteeism: Threat to Healthcare



- Presenteeism is a major threat to patient and employee health

## “Stay home, save lives”: Characterizing sickness presenteeism among healthcare personnel during the COVID-19 pandemic

### Background

Extreme demands on healthcare systems and services due to the SARS-CoV-2 pandemic have altered the workplace environment, potentially affecting sickness presenteeism, defined as presenting to work with symptoms of illness.

Previous literature on presenteeism has focused on chronic illness, job performance and/or economic costs for organizations. Little is known about upstream motivators for infectious illness presenteeism.


### Methods

We surveyed 586 healthcare personnel (HCP) at a large, academic medical center in North Carolina about their experiences, perceptions and behaviors related to sickness presenteeism during the COVID-19 pandemic. We measured frequency of and motivators for reported presenteeism with any symptoms of infectious illness as well as upper respiratory infection (URI) symptoms specifically. Using chi square statistics and logistic regression modeling, we compared these reports between demographic groups.


### Study population

- Respondents to the survey were mostly:
- Female (85%)
  - White (64%), Black (11%), or >1 race (16%)
  - Worked as direct patient care providers (60%)
  - Bachelor's (43%) or Master's degree (25%) holders
  - Reported age categories 30 - 59 (77%)

### Concurrent Motivators



### Primary Motivators



### Results

60% of HCP reported working with any symptoms of infectious illness at least once since March 2020.

Of them, 84% reported more than one motivation.

Perceived low risk of COVID-19 (primarily mild symptoms) was the primary motivator for 40% of people working with any symptoms.

Authors:  
 Amanda Brown Marulak MPH  
 David J. Weber MD MPH  
 Cynthia Culbreth BSN RN  
 Erica Pettigrew MD JD MPH  
 Lisa Stancil MPH  
 Emily Sicker-Bennett PhD MS  
 Contact: okamy@unc.edu





**Thank You!**

[Erica\\_pettigrew@med.unc.edu](mailto:Erica_pettigrew@med.unc.edu)

